Drugs and other treatments can be quite effective at killing cancer cells, yet many fall short as they struggle to penetrate ...

Learn how nanoparticles cross the blood-brain barrier (BBB) and explore their potential in treating neurological disorders through targeted drug delivery.

Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, today reported its financial ...

The FDA cleared the investigational new drug (IND) application for EVM14. EVM14 is an off-the-shelf tumor-associated antigen ...

The FDA has granted approval for the IND application of Everest Medicines’ tumour-associated antigen (TAA) vaccine, EVM14.

Fish oil supplements, delivering higher EPA doses, significantly reduced the number and procoagulant activity of ...

The company expects next quarter to read out initial data from its Heart-2 trial, which is testing a one-time treatment for people with genetically elevated cholesterol.

Scientists are developing novel nanoparticles that could dramatically increase the effectiveness of immunotherapies when ...

University of Queensland researchers are designing nanotechnology they believe could improve how we treat the most aggressive form of breast cancer.

Customers looking for an mRNA therapeutic partner should prioritize operational excellence and choose flexible CDMOs.

Sebastien Beauzile, 21, is the first New Yorker to have received the breakthrough Lyfgenia treatment, according to the New ...

EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical ...